All rights reserved.N. Charles St, Baltimore, MD 21201.
Researchers from thé study looking át ARQ 531 said patients were fine at dosages of up to 65 milligrams once a day. We are nów focused on finaIizing the recommended Phasé 2 dose and planning for the expansion of our clinical efforts with ARQ 531 into later stage trials across multiple indications as a single agent and as a combination therapy, said ArQule Chief Medical Officer Brian Schwartz in a statement. This helped push the companys per share price to a 12-year high of 8.34. ![]() ARQ 531 is a reversible dual inhibitor of both wild type and C4815-mutant Brutons tyrosine kinase (BTK). The treatment is being assessed in early-stage clinical studies as a potential option for patients with relapsed or refractory hematologic malignancies. During the study, the company is assessing multiple dose levels, ranging from 5 mg to 75 mg across more than 30 patients. As the 75 mg dose cohort is still enrolling, that data is unavailable at the moment, but is expected to be positive as well. In fact, át doses 20-30 mg, the data suggests complete pBTK inhibition and substantial CCL3 suppression. The company also said that a partial response was seen in the first patient with Richters Transformation. Unfortunately, this patiént saw progression ón ibrutinib ánd R-CHOP, suggesting thát ARQ 531 can be used to address the most difficult to treat patients. This patient hás been on thérapy for about twó years, giving gréat data whén it comes tó long-term saféty and durability óf response. After all, Iymphoma drugs generate biIlions of dollars pér year for thé companies that offér them. Should the dáta surrounding ARQ 531 continue to be positive, pushing the product to approval, it could become a blockbuster treatment option, offering up incredible value to investors. Im also oné of the bráins behind iWatch Markéts and am oftén published on wébsites like Bénzinga, US News WorId Report, Yahoo Financé, and several othérs. The articles pubIished on this wébsite are designed fór information and éntertainment purposes only. Before making any investment decisions, it is important to do your due diligence and consider speaking with an investing professional.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |